ATYR
NASD aTyr Pharma, Inc.$0.2872 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2872, $0.0088 below the day’s high of $0.2960
- YTD change
- -63.33%
- vs 20-day SMA
- -24.91%
- vs 200-day SMA
- -56.55%
Price ranges
Price & Performance
-0.54 (-65.15%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.1% away from all-time highs of $7.2904
- ATYR is down 63% since the beginning of the year
- ATYR is down 60% over the past 12 months
- ATYR is down 42% over the past 1 month
- 12% of all ATYR investors are betting against ATYR
ATYR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -63.0%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0007
- Last 5 days
- -14.93%
- vs 8-day SMA
- -10.83%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
